ASH 2016 Annual Meeting Highlights in Hodgkin Lymphoma


Immunotherapy
Stephen M. Ansell, MD, PhD

Begin


Biomarkers
Bruce D. Cheson, MD, FACP, FAAS

Begin


PET-adapted Therapy
Martin Hutchings, MD, PhD

Begin


Anti-CD30 Therapy
Alison J. Moskowitz, MD

Begin

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved